Cargando…
A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis B
In chronic Hepatitis B Virus (HBV) infections HBV-specific T cells are functionally impaired. Immunotherapy may restore HBV-specific T cell responses essential for sustained disease remission off-treatment and induction of a functional cure. Chimigen® Molecules are fusion proteins of antigen(s) with...
Autores principales: | Ma, Allan, Motyka, Bruce, Gutfreund, Klaus, Shi, Yuenian Eric, George, Rajan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227630/ https://www.ncbi.nlm.nih.gov/pubmed/31687879 http://dx.doi.org/10.1080/21645515.2019.1689080 |
Ejemplares similares
-
A dendritic cell-targeted chimeric hepatitis B virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo
por: George, Rajan, et al.
Publicado: (2019) -
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
por: Martin, Perrine, et al.
Publicado: (2015) -
Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma
por: Hänsch, Lena, et al.
Publicado: (2023) -
Lack of infectivity of HBV in feces from patients with chronic hepatitis B virus infection, and infection using chimeric mice
por: Komatsu, Haruki, et al.
Publicado: (2015) -
Dendritic Cells and Their Immunotherapeutic Potential for Treating Type 1 Diabetes
por: Khan, Farhan Ullah, et al.
Publicado: (2022)